Development of an Inactivated Vaccine against SARS CoV-2.
Development of an Inactivated Vaccine against SARS CoV-2.
复制标题
DOI：
10.3390/vaccines9111266
复制
发表时间：
2021-11-02
期刊：
影响因子：
7.8
通讯作者：
Ozdarendeli A
中科院分区：
文献类型：
--
作者：
Pavel STI;Yetiskin H;Uygut MA;Aslan AF;Aydın G;İnan Ö;Kaplan B;Ozdarendeli A
The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates in preclinical development worldwide as per the WHO on 1 October 2021. The various types of vaccines that are currently approved for emergency use include viral vectors (e.g., adenovirus, University of Oxford/AstraZeneca, Gamaleya Sputnik V, and Johnson & Johnson), mRNA (Moderna and Pfizer-BioNTech), and whole inactivated (Sinovac Biotech and Sinopharm) vaccines. Amidst the emerging cases and shortages of vaccines for global distribution, it is vital to develop a vaccine candidate that recapitulates the severe and fatal progression of COVID-19 and further helps to cope with the current outbreak. Hence, we present the preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERUCoV-VAC) formulated in aluminium hydroxide, in three animal models, BALB/c mice, transgenic mice (K18-hACE2), and ferrets. The hCoV-19/Turkey/ERAGEM-001/2020 strain was used for the safety evaluation of ERUCoV-VAC. It was found that ERUCoV-VAC was highly immunogenic and elicited a strong immune response in BALB/c mice. The protective efficacy of the vaccine in K18-hACE2 showed that ERUCoV-VAC induced complete protection of the mice from a lethal SARS-CoV-2 challenge. Similar viral clearance rates with the safety evaluation of the vaccine in upper respiratory tracts were also positively appreciable in the ferret models. ERUCoV-VAC has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 3 clinical development (NCT04942405). The name of ERUCoV-VAC has been changed to TURKOVAC in the phase 3 clinical trial.
登录
查看更多内容
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
影响因子：
4.7
作者：
Gralinski, Lisa E.;Menachery, Vineet D.
通讯作者：
Menachery, Vineet D.
影响因子：
3.1
作者：
Cui, Xiaoni;Wang, Pengxiang;Wei, Zhun
通讯作者：
Wei, Zhun
影响因子：
3.7
作者：
Enkirch T;von Messling V
通讯作者：
von Messling V
DOI：
10.3390/v13010113
发表时间：
2021-01-15
期刊：
Viruses
影响因子：
--
作者：
Everett HE;Lean FZX;Byrne AMP;van Diemen PM;Rhodes S;James J;Mollett B;Coward VJ;Skinner P;Warren CJ;Bewley KR;Watson S;Hurley S;Ryan KA;Hall Y;Simmons H;Núñez A;Carroll MW;Brown IH;Brookes SM
通讯作者：
Brookes SM